Compare IDEXX Laboratories, Inc. (IDXX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs TKO Group Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while TKO Group Holdings Inc trades at $195.16 (market cap $14.24B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.2× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.6% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TKO | |
|---|---|---|
Market Cap | $46.22B | $14.24B |
Sector | Health | Technology |
52-Week High | $766.68 | $224.96 |
52-Week Low | $526.44 | $176.49 |
Enterprise Value | $47.12B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
TKO trades at $195.14, up 3.02% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. Recent Q2 2026 results showed revenue of $1.55 billion, an 18% YoY increase, though EPS of $1.34 missed expectations. The company raised full-year guidance, reflecting confidence in media rights and live events. Analyst consensus is strongly bullish with an average price target of $228.17, representing 17% upside from current levels.
TKO's growth trajectory is supported by expanding media deals and global events, but high valuation multiples (P/E 68.33) pose risks if execution falters. Key opportunities include continued revenue momentum from UFC and WWE, while risks involve earnings volatility and competitive pressures. The stock remains attractive for growth-oriented investors despite premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
